The oral JAK inhibitor ruxolitinib is associated with significant clinical improvement in patients with steroid-refractory or steroid-dependent graft-versus-host disease (GVHD), according to results from a phase 3 trial.
Corticosteroids are the first-line treatment for GVHD, but “about 40% of patients are steroid refractory or steroid dependent and require additional treatment. The best second-line therapy option has not yet been defined,” reported Robert Zeiser, MD, PhD, the